AI Article Synopsis

  • SARS-CoV-2 variants continue to pose challenges in the COVID-19 pandemic, highlighting the need for new antiviral drugs despite existing vaccines and treatments.
  • Astersaponin I (AI), a natural compound found in Aster koraiensis, has been shown to effectively block SARS-CoV-2 from entering host cells by enhancing plasma membrane cholesterol and preventing viral fusion.
  • AI remains effective against various SARS-CoV-2 variants and suggests potential as a broad-spectrum antiviral agent for both the current pandemic and future viral outbreaks.

Article Abstract

The continuous emergence of SARS-CoV-2 variants prolongs COVID-19 pandemic. Although SARS-CoV-2 vaccines and therapeutics are currently available, there is still a need for development of safe and effective drugs against SARS-CoV-2 and also for preparedness for the next pandemic. Here, we discover that astersaponin I (AI), a triterpenoid saponin in Aster koraiensis inhibits SARS-CoV-2 entry pathways at the plasma membrane and within the endosomal compartments mainly by increasing cholesterol content in the plasma membrane and interfering with the fusion of SARS-CoV-2 envelope with the host cell membrane. Moreover, we find that this functional property of AI as a fusion blocker enables it to inhibit the infection with SARS-CoV-2 variants including the Alpha, Beta, Delta, and Omicron with a similar efficacy, and the formation of syncytium, a multinucleated cells driven by SARS-CoV-2 spike protein-mediated cell-to-cell fusion. Finally, we claim that the triterpene backbone as well as the attached hydrophilic sugar moieties of AI are structurally important for its inhibitory activity against the membrane fusion event. Overall, this study demonstrates that AI is a natural viral fusion inhibitor and proposes that it can be a broad-spectrum antiviral agent against current COVID-19 pandemic and future outbreaks of novel viral pathogens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568284PMC
http://dx.doi.org/10.1016/j.antiviral.2022.105428DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 variants
12
aster koraiensis
8
natural viral
8
viral fusion
8
fusion blocker
8
sars-cov-2
8
infection sars-cov-2
8
covid-19 pandemic
8
plasma membrane
8
fusion
6

Similar Publications

SARS-CoV-2 variants are mainly defined by mutations in their spike. It is therefore critical to understand how the evolutionary trajectories of spike affect virus phenotypes. So far, it has been challenging to comprehensively compare the many spikes that emerged during the pandemic in a single experimental platform.

View Article and Find Full Text PDF

SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has triggered several therapeutic strategies against COVID-19 relying on the use of ACE2 recombinant proteins as decoy receptors. In this work, we propose an ACE2 silent Fc fusion protein (ACE2-hFcLALA) as a candidate therapy against COVID-19.

View Article and Find Full Text PDF

Background: The emergence of new SARS-CoV-2 variants poses a new challenge for the treatment of immunocompromised patients against COVID-19. In this context, high titer COVID-19 Convalescent Plasma (CCP) is one of the few available therapeutics for these patients. We have revisited the selection of CCP samples and its efficacy against Omicron XBB.

View Article and Find Full Text PDF

Background: Several variants of SARS-CoV-2 have a demonstrated impact on public health, including high and increased transmissibility, severity of infection, and immune escape. Therefore, this study aimed to determine the SARS-CoV-2 lineages and better characterize the dynamics of the pandemic during the different waves in Guinea.

Methods: Whole genome sequencing of 363 samples with PCR cycle threshold (Ct) values under thirty was undertaken between May 2020 and May 2023.

View Article and Find Full Text PDF

Studies of acute and post-acute COVID-19, including their biology, prevention, and treatment, were presented at the 2024 Conference on Retroviruses and Opportunistic Infections. Numerous studies reported on the impact of hybrid immunity (ie, from a combination of prior infection and vaccination) on the natural history, pathogenesis, and outcomes of infection with modern SARS-CoV-2 variants. Several studies demonstrated the continued benefit of SARS-CoV-2 vaccination and the effect of treatment, particularly in the setting of severe disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!